Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex therapeutic classes.
Christina Satterwhite, PhD
Advertisement
Christina Satterwhite, PhD, is senior director, global laboratory sciences at Charles River Laboratories.
Articles by Christina Satterwhite, PhD
Advertisement
Latest Updated Articles
Emerging Therapies Test Existing Bioanalytical MethodsApril 15th 2019
Advertisement
Advertisement
Trending on BioPharm International
1
Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
The BioPharm Brief: Lung Injury Survival, Alzheimer Prevention, and Longer Dosing Intervals
4
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
5